UPCC 07419: A Phase 1b/2a Multicenter Open-Label Dose Escalation Study to Determine the Maximum Tolerated Dose Assess the Safety Tolerability Pharmacokinetics and Efficacy Of Cc-220 Monotherapy and In Combination With Other Treatments In Subjects With Relapsed and Refractory Multiple Myeloma

Recruiting

99 years or below

All

Phase 2

1 Location

Brief description of study

The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Apr 2021. Study ID: 832983

Find a site

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).